Please ensure Javascript is enabled for purposes of website accessibility


Our Leadership

Pasithea team is comprised of experts with decades of experience in research and drug development in neuroscience and and extensive know-how at leading biopharmaceutical companies.

Executive Team

Professor Lawrence Steinman, MD, PhD

MD Chairman

Lawrence is a professor of neurology and neurological sciences, pediatrics and genetics at Stanford Medical School, where he leads a research team that focuses on the pathogenesis of autoimmune diseases. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation, leading to the development of the drug Tysabri.

Lawrence received his doctoral degree from Harvard Medical School, and he was a post-doctoral fellow in chemical immunology at the Weizmann Institute of Science in Israel. He has received many honors and awards, including the John M. Dystel Prize from the American Academy of Neurology and the National MS Society for his research on multiple sclerosis (MS), the Charcot Prize for Lifetime Achievement in MS research and the Cerami Prize for Translational Research. He has twice been awarded the Senator Jacob Javits Neuroscience Investigator Award by the National Institute of Neurological Diseases and Stroke. Lawrence is a member of the National Academy of Sciences and the National Academy of Medicine.

Tiago Reis Marques, MD, PhD

Chief Executive Officer

Dr. Marques is a fellow at Imperial College London and a lecturer at the Institute of Psychiatry, King’s College London. Dr. Marques is also a psychiatrist at Maudsley Hospital, rated as one of the top three psychiatry centres in the world. His research focuses on topics including the mechanism of action of psychiatric medication and the unveil of novel treatment targets. Dr. Marques has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.

Graeme Currie, PhD

Chief Development Officer

Graeme has over 30 years of drug development experience in both pharmaceutical and biotechnology companies.

Graeme has held senior leadership roles at both public and privately held biotech organizations leading operations and development activities.  

Graeme held C-suite or senior management roles at BioClin Theraeutics, Dynavax technologies, Tolerion Inc., Regeneron Pharmaceuticals, Sepracor, Protein Design labs and Gilead Sciences.

Graeme received a BSc from the University of Salford, and a Ph.D. from Aston University in the UK. Graeme has been involved in the development of 8 approved new drugs.

Dan Schneiderman

Chief Financial Officer

Mr. Schneiderman has over 20 years of capital markets and finance operations experience. Mr. Schneiderman has held senior financial leadership positions at primarily small cap public healthcare and biotechnology companies, including First Wave BioPharma, Biophytis and MetaStat. Previously, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners, a boutique investment bank providing capital raising, advisory and merchant banking services and worked as an investment banking analyst at H.C. Wainwright & Co. Mr. Schneiderman holds a bachelor’s degree in economics from Tulane University.